Skip to main content
    C

    Collegium Pharmaceutical Inc (COLL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.43
    +0.11 (+0.43%)

    Market Cap: $786.83M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Collegium Pharmaceutical Inc (COLL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Collegium Pharmaceutical reported revenue of $780.57M for the fiscal year ended Dec 31, 2025, up 23.6% from the year before. That year, net income was $62.87M with a net margin of 8.1%, operating cash flow was $329.32M and free cash flow was $327.58M. The quarter ended Sep 30, 2026 had revenue of $216.34M and net income of $21.76M.

    Revenue and Margins

    The operating margin was 23.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.71M, a compound annual rate of 97.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$780.57M+23.6%59.3%23.0%8.1%
    Dec 2024$631.45M+11.4%59.8%26.9%11.0%
    Dec 2023$566.77M+22.2%57.5%29.5%8.5%
    Dec 2022$463.93M+67.6%45.2%7.2%-5.4%
    Dec 2021$276.87M-10.7%54.4%6.4%25.8%
    Dec 2020$310.02M+4.5%58.0%18.1%8.6%
    Dec 2019$296.70M+5.8%34.7%-8.0%-7.7%
    Dec 2018$280.41M+884.7%40.9%-7.4%-14.0%
    Dec 2017$28.48M+1564.3%90.9%-264.9%-262.9%
    Dec 2016$1.71MN/A87.6%-5498.7%-5504.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 9.1% from the year before. In the quarter ended Sep 2026, net income fell 30.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$780.57M$631.45M$566.77M$463.93M$276.87M$310.02M$296.70M$280.41M$28.48M$1.71M
    Cost of revenue$317.31M$254.10M$240.60M$254.44M$126.25M$130.18M$193.66M$165.68M$2.60M$213.00K
    Gross profit$463.26M$377.34M$326.17M$209.49M$150.62M$179.84M$103.04M$114.74M$25.88M$1.50M
    Research and development$0$0$0$3.98M$9.45M$9.77M$10.34M$8.66M$8.57M$14.95M
    Operating income$179.64M$169.90M$166.96M$33.32M$17.63M$56.23M-$23.75M-$20.68M-$75.45M-$94.08M
    Net income$62.87M$69.19M$48.16M-$25.00M$71.52M$26.75M-$22.72M-$39.13M-$74.86M-$94.18M
    EBITDA$409.98M$343.04M$323.62M$180.54M$89.95M$126.75M-$8.27M$90.22M-$74.89M-$93.46M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$216.34M$199.88M$193.52M$205.45M$209.36M$188.00M$177.76M$181.95M$159.30M$145.28M$144.92M$149.75M
    Gross profit$125.42M$110.29M$117.25M$128.38M$129.17M$108.38M$97.32M$98.29M$96.79M$90.81M$91.46M$94.63M
    Operating income$28.72M$3.70M$30.90M$60.76M$62.09M$35.10M$21.69M$38.11M$34.84M$47.47M$49.47M$61.69M
    Net income$21.76M-$15.05M$14.50M$16.96M$31.51M$11.98M$2.42M$12.54M$9.34M$19.61M$27.71M$31.94M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $809.33M exceeded cash and equivalents by $578.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.66B$1.66B$1.14B$1.17B$692.08M$643.84M$306.30M$291.25M$135.57M$162.02M
    Current assets$691.41M$482.26M$537.60M$419.99M$315.54M$277.89M$255.72M$237.51M$133.48M$158.57M
    Cash and equivalents$231.25M$70.56M$238.95M$173.69M$186.43M$174.12M$170.02M$146.63M$118.70M$153.22M
    Total liabilities$1.36B$1.43B$947.88M$979.29M$489.15M$457.81M$218.87M$199.66M$31.49M$27.11M
    Short-term debt$29.00M$93.54M$183.33M$162.50M$48.35M$47.49M$3.83M$1.64M$1.48M$2.67M
    Long-term debt$780.33M$787.90M$483.84M$538.45M$201.63M$209.59M$7.67M$9.86M$0$1.48M
    Shareholder equity$301.68M$228.84M$195.43M$194.84M$202.93M$186.03M$87.43M$91.58M$104.08M$134.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.10B$2.14B$1.65B$1.66B$1.61B$1.59B$1.63B$1.66B$1.64B$1.05B$1.11B$1.14B
    Total liabilities$1.80B$1.82B$1.34B$1.36B$1.33B$1.36B$1.40B$1.43B$1.40B$836.80M$892.08M$947.88M
    Cash and equivalents$144.80M$129.47M$268.65M$251.10M$150.10M$117.35M$96.19M$70.56M$38.96M$172.89M$228.61M$238.95M
    Shareholder equity$296.44M$311.91M$312.42M$301.68M$274.81M$232.21M$234.43M$228.84M$234.28M$216.58M$222.17M$195.43M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.5% of operating cash flow. Share repurchases came to 7.7% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$329.32M$204.98M$274.75M$124.23M$103.56M$93.94M$27.78M$169.39M-$67.02M-$75.05M
    Capital expenditures$1.74M$1.65M$461.00K$1.62M$1.94M$5.55M$6.44M$5.48M$990.00K$477.00K
    Free cash flow$327.58M$203.33M$274.29M$122.61M$101.61M$88.40M$21.34M$163.91M-$68.01M-$75.53M
    Dividends paidN/AN/A$9.10MN/A$12.71M$7.33MN/AN/A$736.00K$24.57M
    Share repurchases$25.10M$60.02M$75.00M$14.06M$47.86M$0$0$30.00KN/AN/A
    Investing cash flow-$63.53M-$287.76M-$70.81M-$573.69M-$1.94M-$373.77M-$6.44M-$24.35M-$990.00K-$2.98M
    Financing cash flow-$110.25M-$60.60M-$140.18M$436.72M-$89.30M$286.47M$2.04M-$117.20M$33.48M$135.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$86.54M$71.32M$57.11M$123.05M$78.44M$72.44M$55.40M$84.64M-$9.00M$67.40M$61.94M$73.34M
    Capital expenditures$277.00K$496.00K$270.00K$689.00K$188.00K$65.00K$798.00K$570.00K$244.00K$270.00K$568.00K$164.00K
    Free cash flow$86.26M$70.83M$56.84M$122.36M$78.25M$72.37M$54.60M$84.07M-$9.24M$67.13M$61.37M$73.17M
    Last 12 quarters

    Frequently Asked Questions About COLL

    What is Collegium Pharmaceutical's annual revenue?

    Collegium Pharmaceutical reported revenue of $780.57M for the fiscal year ended Dec 31, 2025.

    How fast is Collegium Pharmaceutical's revenue growing?

    Revenue was up 23.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 18.9%.

    Is Collegium Pharmaceutical profitable?

    Yes. Collegium Pharmaceutical reported net income of $62.87M for the fiscal year ended Dec 31, 2025, with a net margin of 8.1%.

    How much free cash flow does COLL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $329.32M minus capital expenditures of $1.74M produced free cash flow of $327.58M.

    How much debt does Collegium Pharmaceutical have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $780.33M, short-term debt of $29.00M and cash and equivalents of $231.25M.